Cantai Therapeutics develops drug candidates to treat autoimmune and inflammatory disorders by developing cytokine-targeting bispecific antibodies that meaningfully improve the status quo for the millions of patients suffering from immune-mediated and autoimmune diseases.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 11/20/23 | undisclosed | Seed |
82VS Agent Capital Tellus BioVentures | undisclosed |
